AbSci Corp.
https://www.absci.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From AbSci Corp.
Almirall Goes All In On Generative AI
Dermatology-focused Almirall S.A. is partnering with Microsoft for generative artificial intelligence capabilities. It is the second generative AI-based collaboration announced by Almirall in several months.
Gen AI Companies Shine In Drug Development
A string of AI-focused deals in 2023 and two late-year gen AI-specific agreements may presage a strong 2024 for drug discovery companies employing AI.
Deal Watch: Vanda Buys US, Canadian Rights To J&J’s Ponvory
Plus deals involving Bristol Myers Squibb/Avidity, Aexon/NLS, Boehringer Ingelheim/Phenomic AI, AnaptysBio/Centessa and Biodexa/Adhera/Melior.
Almirall Enlists Absci’s AI Expertise For Dermatology Drug Discovery
Deal Snapshot: In Almirall’s first de novo artificial intelligence drug discovery and development collaboration, the company will pay up to $650m to work with Absci on two dermatology candidates.
Company Information
- Industry
- Pharmaceuticals
- Contract Manufacturing Organization
-
Digital Health
- Artificial Intelligence
-
Biotechnology
- Drug Discovery Tools
- Synthesis Technologies, Production Processes
- Other Names / Subsidiaries
-
- Denovium, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice